Vycor Medical (VYCO) 10-Q 12 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 08, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'VYCOR MEDICAL INC	'
Entity Central Index Key	'0001424768	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Document Type	'10-Q	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	10,736,338

Consolidated_Balance_Sheets_Un

Consolidated Balance Sheets (Unaudited) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current Assets	'	'
Cash	$2,840,052	$31,303
Trade accounts receivable, net of allowance for doubtful accounts of $6,470 and $6,474	196,907	212,660
Inventory	239,673	206,926
Prepaid expenses and other current assets	178,146	208,063
Total Current Assets	3,454,778	658,952
Fixed assets, net of accumulated depreciation of $955,464 and $830,291	642,703	706,197
Intangible and Other assets:	'	'
Trademarks	251,157	251,157
Patents, net of accumulated amortization of $402,048 and $328,319	376,565	444,095
Website, net of accumulated amortization of $18,444 and $17,228	14,306	1,680
Security deposits	53,169	53,169
Total Intangible and Other assets	695,197	750,101
TOTAL ASSETS	4,792,678	2,115,250
Current Liabilities	'	'
Accounts payable	145,096	254,024
Accrued interest: Related Party	33,890	238,299
Accrued interest: Other	17,630	147,985
Accrued liabilities	278,743	1,776,867
Other current liabilities	126,346	61,576
Derivative liability	37,152	'
Notes payable: Related Party	'	2,373,556
Notes payable: Other	311,445	578,186
TOTAL CURRENT LIABILITIES	950,302	5,430,493
Notes payable long-term: Related Party	2,247,037	'
Notes payable long-term: Other	108,550	'
TOTAL LIABILITIES	3,305,889	5,430,493
STOCKHOLDERS' EQUITY ( DEFICIENCY)	'	'
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, 1.0 and 16.2 issued and outstanding as at June 30, 2014 and December 31, 2013 respectively	'	1
Common Stock, $0.0001 par value, 25,000,000 shares authorized, 10,835,945 and 6,757,225 shares issued and outstanding at June 30, 2014 and December 31, 2013 respectively	1,083	675
Additional Paid-in Capital	20,624,282	13,762,689
Treasury Stock (103,334 shares of Common Stock as of June 30, 2014 and December 31, 2013 respectively, at cost)	-1,033	-1,033
Accumulated Deficit	-19,098,800	-17,032,405
Accumulated Other Comprehensive Income	-38,743	-45,170
Total Stockholders' Equity (Deficiency)	1,486,789	-3,315,243
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY( DEFICIENCY)	$4,792,678	$2,115,250

Recovered_Sheet1

Consolidated Balance Sheets (unaudited) (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Consolidated Balance Sheets [Abstract]	'	'
Allowance for doubtful accounts receivable	$6,470	$6,474
Accumulated depreciation	955,464	830,291
Accumulated amortization, Patents	402,048	328,319
Accumulated amortization, Website	$18,444	$17,228
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	1	16.2
Preferred stock, shares outstanding	1	16.2
Common Stock, par value (in dollars per share)	$0.00	$0.00
Common Stock, shares authorized	25,000,000	25,000,000
Common Stock, shares issued	10,835,945	6,757,225
Common Stock, shares outstanding	10,835,945	6,757,225
Treasury Stock, shares	103,334	103,334

Consolidated_Statement_of_Oper

Consolidated Statement of Operations (Unaudited) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Statement of Operations [Abstract]	'	'	'	'
Revenue	$298,540	$234,954	$656,662	$466,628
Cost of Goods Sold	35,767	27,894	78,724	57,912
Gross Profit	262,773	207,060	577,938	408,716
Operating expenses:	'	'	'	'
Research and development	37,395	21,285	52,751	52,635
Depreciation and Amortization	98,997	89,276	193,093	175,546
General and administrative	829,989	706,111	2,028,240	1,389,769
Total Operating expenses	966,381	816,672	2,274,084	1,617,950
Operating loss	-703,608	-609,612	-1,696,146	-1,209,234
Other expense	'	'	'	'
Interest expense - Related Party	-33,613	-32,811	-67,442	-61,778
Interest expense - Other	-12,327	-14,128	-26,621	-28,054
Change in fair value derivative liability	-523,277	'	-269,993	'
Total Other expense	-569,217	-46,939	-364,056	-89,832
Net Loss	-1,272,825	-656,551	-2,060,202	-1,299,066
Comprehensive Income (Loss)	'	'	'	'
Foreign Currency Translation Adjustment	-5,560	8,725	-6,193	-11,432
Net Comprehensive Loss	($1,278,385)	($647,826)	($2,066,395)	($1,310,498)
Loss Per Share	'	'	'	'
Basic and diluted	($0.12)	($0.10)	($0.21)	($0.21)
Weighted Average Number of Shares Outstanding	10,570,609	6,264,362	9,787,198	6,107,053

Consolidated_Statement_of_Cash

Consolidated Statement of Cash Flows (Unaudited) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:	'	'
Net comprehensive loss	($2,066,395)	($1,310,498)
Adjustments to reconcile net comprehensive loss to cash used in operating activities:	'	'
Amortization expense	74,944	62,844
Depreciation expense	125,786	126,512
Share based compensation expense	259,727	174,064
Change in fair value of derivative liability	269,993	'
Changes in assets and liabilities:	'	'
Accounts receivable	15,753	51,887
Inventory	-32,747	31,329
Prepaid expenses	-27,535	-4,129
Accounts payable	-68,737	49,853
Accrued interest: Related Party	-218,895	61,777
Accrued interest: Other	-115,868	28,058
Accrued liabilities	-52,990	193,548
Other current liabilities	7,440	-16,302
Cash used in operating activities	-1,829,524	-551,057
Cash flows used in investing activities:	'	'
Purchase of fixed assets	-62,001	-20,116
Acquisition of subsidiary	'	-139,153
Website costs	-13,842	'
Patent costs	-6,199	-58,457
Cash used in investing activities	-82,042	-217,726
Cash flows from financing activities:	'	'
Proceeds from issuance of Common Stock	5,000,000	304,351
Proceeds from issuance of Notes Payable: Related Party	'	442,962
Proceeds from issuance of Notes Payable: Other	28,525	'
Repayment of Notes Payable: Related Party	-126,519	'
Repayment of Notes Payable: Other	-186,716	-28,236
Cash provided by financing activities	4,715,290	719,077
Effect of exchange rate changes on cash	5,025	10,058
Net increase (decrease) in cash	2,808,749	-39,648
Cash at beginning of period	31,303	59,821
Cash at end of period	2,840,052	20,173
Supplemental Disclosures of Cash Flow information:	'	'
Interest paid:	430,208	'
Acquisition of subsidiary: Deferred consideration paid	'	$139,153

Basis_of_Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2014
Basis of Presentation and Formation and Business of the Company [Abstract]	'
BASIS OF PRESENTATION	'
	1.  BASIS OF PRESENTATION
	The consolidated financial statements of the Company present the financial position, results of operations, and cash flows of Vycor Medical, Inc. and its wholly owned subsidiaries (the “Company”). All significant intercompany accounts and transactions have been eliminated. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Commission. In accordance with those rules and regulations certain information and footnote disclosures normally included in comprehensive financial statements have been condensed or omitted pursuant to such rules and regulations. The consolidated balance sheet as of December 31, 2013 derives from the audited financial statements at that date, but does not include all the information and footnotes required by GAAP. These financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.
	The condensed consolidated financial statements for the three and six months ended June 30, 2014 and 2013, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the Company’s financial condition and results of operations. The results of operations for the three and six months ended June 30, 2014 and 2013 are not necessarily indicative of the results to be expected for any other interim period or for the entire year. Certain prior period amounts have been reclassified to conform to the current presentation.

Significant_Accounting_Policie

Significant Accounting Policies	6 Months Ended
	Jun. 30, 2014
Significant Accounting Policies [Abstract]	'
SIGNIFICANT ACCOUNTING POLICIES	'
	2.   SIGNIFICANT ACCOUNTING POLICIES
	Principles of Consolidation
	The consolidated financial statements include the accounts of Vycor Medical, Inc., and its wholly-owned subsidiaries, NovaVision, Inc. (a Delaware corporation), NovaVision GmbH (a German corporation) and Sight Science Limited (a UK corporation), both wholly owned subsidiaries of NovaVision, Inc. The Company is headquartered in Boca Raton, FL. All material inter-company accounts, transactions, and profits have been eliminated in consolidation.
	Recent Accounting Pronouncements
	From time to time new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations and cash flows when implemented.
	Derivative Liability
	The Company accounts for the 34,723 Series A Warrants issued in connection with the Offering (all as defined in Note 5), the holders of which have not waived their anti-dilution rights (as detailed further in Note 5) in accordance with the guidance contained in ASC 815-40-15-7D, whereby under that provision, because they have anti-dilution rights, they do not meet the criteria for equity treatment and must be recorded as a liability. Accordingly, the Company classifies the warrant instrument as a liability at its fair value and adjusts the instrument to fair value at each reporting period. This liability is subject to re-measurement at each balancesheet date until exercised or until the anti-dilution provisions contained within the warrant agreements expire, and is classified in the balance sheet as a current liability. Any change in fair value of the warrant liability is recognized in the Company’s statement of operations as other income (loss).
	Software Development Costs
	The authoritative accounting guidance requires software development costs to be capitalized upon completion of the preliminary project stage.  Accordingly, direct internal and external costs associated with the development of the features and functionality of the Company’s software, incurred during the application development stage, are capitalized and amortized using the straight-line method of the estimated life of five years once the software has been brought into service. Capitalized software development costs for the six months ended June 30, 2014 and 2013 were $55,039 and $0, respectively. During the period the Company’s VRT 7.0 program completed the preliminary project stage, following which there was a capitalization of $25,199 of software development costs. Additional costs of $21,463 were capitalized for the Company’s NeuroEyeCoach program (prior to being brought into service in March 2014 with a total capitalized value of $119,106), and $8,377 for a NeuroEyeCoach retail/physician model.
	Net Loss Per Share
	Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Dilutive potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock and convertible debt.  Such potentially dilutive shares are excluded when the effect would be to reduce a net loss
	per share. No dilution adjustment has been made to the weighted average outstanding common shares in the periods presented because the assumed exercise of outstanding options and warrants and the conversion of preferred stock and debt would be anti-dilutive.
	The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share:
		June 30,		June 30,
		2014		2013
	Stock options outstanding		5,557		5,557
	Warrants to purchase common stock		5,226,523		1,423,123
	Debentures convertible into common stock		477,716		368,727
	Preferred shares convertible into common stock		14,815		320,007
	Total		5,724,611		2,117,414

Notes_Payable

Notes Payable	6 Months Ended
	Jun. 30, 2014
Notes Payable [Abstract]	'
NOTES PAYABLE	'
	3.   NOTES PAYABLE
	Related Party Notes Payable
	As of June 30, 2014 and December 31, 2013 Related Party Notes Payable consists of:
				June 30,				December 31,
				2014				2013
	On December 29, 2009 and February 3, 2010, the Company issued convertible debentures in the amount of $371,362 and $70,000, respectively, payable to Fountainhead Capital Management (“Fountainhead”), the beneficial owner of more than 50% of the Company’s common stock. These debentures accrue interest at a rate of 6% per annum. The Holder is entitled to convert all or any amount of the principal face amount of the debentures then outstanding into shares of common stock of the Company at the conversion price of $1.88 per share, subject to adjustment, and does not require bifurcation. These debentures were originally due August 31, 2010 and the due date has been extended to January 2, 2017, subject to certain early repayment provisions. (On August 5, 2014 the holder agreed to exchange the note into series D convertible preferred stock of Vycor, see Note 11)			441,362				441,362
				June 30,				December 31,
				2014				2013
	On March 31, 2010 and October 14, 2010, the Company issued convertible debentures payable to Fountainhead in the amount of $85,000 and $90,000, respectively. These debentures accrue interest at a rate of 6%. The Holder is entitled to convert all or any amount of the principal face amount of the debentures then outstanding into shares of common stock of the Company at the conversion price of $2.63 per share, subject to adjustment and does not require bifurcation. The debentures were originally due August 31, 2011, and the due date has been extended to January 2, 2017, subject to certain early repayment provisions. (On August 5, 2014 the holder agreed to exchange the note into series D convertible preferred stock of Vycor, see Note 11)			175,000				175,000
	On October 26, 2010 and November 15, 2010, the Company issued debentures payable to Fountainhead in the amount of $77,500 and $322,500, respectively. These debentures accrue interest at a rate of 6% per annum. These debentures were originally due August 31, 2011 and the due date has been extended to January 2, 2017, subject to certain early repayment provisions. (On August 5, 2014 the holder agreed to exchange the note into series D convertible preferred stock of Vycor, see Note 11)			400,000				400,000
	On November 15, 2010, the Company issued a convertible debenture in the amount of $350,000 payable to Peter Zachariou, a Director of the Company. This debenture accrues interest rate of 6% per annum. The Holder is entitled to convert all or any amount of the principal face amount of the debenture then outstanding into shares of common stock of the Company at the conversion price of $2.85 per share, subject to adjustment and does not require bifurcation. On December 20, 2010, the Company repaid $50,000 of this debenture and removed the convertible rights. The debentures were originally due December 31, 2012 and the due date has been extended   to January 2, 2017, subject to certain early repayment provisions. (On August 5, 2014 the holder agreed to exchange the note into series D convertible preferred stock of Vycor, see Note 11)			300,000				300,000
	In the period July to December 2012 the Company issued short term, unsecured notes payable to Fountainhead in the aggregate amount of $300,900. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. The due date has been extended  to January 2, 2017, subject to certain early repayment provisions. (On August 5, 2014 the holder agreed to exchange the note into series D convertible preferred stock of Vycor, see Note 11)			300,900				300,900
	In the period August to December 2012 the Company issued short term, unsecured notes payable to Peter Zachariou in the aggregate amount of $115,550. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. The due date has been extended  to January 2, 2017, subject to certain early repayment provisions. (On August 5, 2014 the holder agreed to exchange the note into series D convertible preferred stock of Vycor, see Note 11)			115,550				115,550
	In the period January to September 2013 the Company issued short term, unsecured notes payable to Fountainhead in the aggregate amount of $325,744. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. The due date has been extended  to January 2, 2017, subject to certain early repayment provisions (On August 5, 2014 the holder agreed to exchange the note into series D convertible preferred stock of Vycor, see Note 11)			324,225				324,225
				June 30,				December 31,
				2014				2013
	In the period August 9 to December 2013 the Company issued short term, unsecured notes payable to Fountainhead in the aggregate amount of $91,519. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. These notes were repaid in January and February 2014.			—				91,519
	In the period January to September 2013 the Company issued short term, unsecured notes payable to Peter Zachariou in the aggregate amount of $210,000. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. The due date has been extended  to January 2, 2017, subject to certain early repayment provisions. (On August 5, 2014 the holder agreed to exchange the note into series D convertible preferred stock of Vycor, see Note 11)			190,000				190,000
	In the period August 9 to December 2013 the Company issued short term, unsecured notes payable to Peter Zachariou in the aggregate amount of $20,000. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. This note was repaid in February 2014			—				20,000
	In the period August 9 to December 2013 the Company issued short term, unsecured notes payable to David Cantor, in the aggregate amount of $15,000. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. This note was repaid in 2014.			—				15,000
	Total Related Party Notes Payable:		$	2,247,037			$	2,373,556
	Other Notes Payable
	As of June 30, 2014 and December 31, 2013 Other Notes Payable consists of:
				June 30,				December 31,
				2014				2013
	On March 25, 2011 the Company issued a term note for $300,000 to EuroAmerican Investment Corp. (“EuroAmerican”). The term note bears interest at 16% per annum and was due June 25, 2011. In connection with the loan the Company also issued EuroAmerican warrants to purchase 400,000 shares of the Company’s common stock at an exercise price of $4.50 per share for a period of three (3) years. On June 25, 2011 the due date for this note was extended to September 25, 2011 and the Holder was granted the right to convert all or any amount of the principal face amount of the debenture then outstanding and accrued interest into shares of common stock of the Company an adjusted  conversion price of $1.80 per share, subject to adjustment and does not require bifurcation. The due date for this note has been extended to January 2, 2015, subject to certain early repayment provisions.			300,000				300,000
				June 30,				December 31,
				2014				2013
	In the period August to December 2012 the Company issued short term, unsecured notes payable to Craig Kirsch in the aggregate amount of $98,550. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. The due date for this note has been extended  to January 2, 2017, subject to certain early repayment provisions. (On August 5, 2014 the holder agreed to exchange the note into series D convertible preferred stock of Vycor, see Note 11)			98,550				98,550
	In September 2012 the Company issued short term, unsecured notes payable to Osbaldo Trading Limited in the amount of $42,900. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. This note was repaid in June 2014.			—				42,900
	In the period June to September 2013 the Company issued short term, unsecured notes payable to Craig Kirsch in the aggregate amount of $10,000. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. The due date for this note has been extended  to January 2, 2017, subject to certain early repayment provisions.(On August 5, 2014 the holder agreed to exchange the note into series D convertible preferred stock of Vycor, see Note 11)			10,000				10,000
	In the period August 9 to December 2013 the Company issued short term, unsecured notes payable to Craig Kirsch in the aggregate amount of $3,000. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. This note was repaid in February 2014.			—				3,000
	On October 22, 2013 the Company issued a term note for $100,000 to EuroAmerican Investment Corp. (“EuroAmerican”). The term note bears interest at 16% per annum and was due November 30, 2013. This note was repaid in January 2014.			—				100,000
	Insurance policy finance agreements. During the six months ended June 30, 2014 the Company received proceeds from Insurance policy finance agreements of $28,525 and made repayments of $40,816			11,445				23,736
	Total Other Notes Payable:		$	419,995			$	578,186
	The following is a schedule of future minimum loan repayments:
		Six months ending June 30				Related Party				Other
		2014				—				311,445
		2015				—				—
		2016				—				—
		2017				2,247,037				108,550
					$	2,247,037			$	419,995
	The company assesses the value of the beneficial conversion feature of its convertible debt by determining the intrinsic value of such conversion, under ASC 470, at the time of issuance. At the time of issuance of each of the convertible debt instruments set out above, the fair value of the stock was either the same or less than the conversion price, and so there was no value attributable to any beneficial conversion feature.
	On August 5, 2014, each of the convertible debt instruments set out above were exchanged for Series D convertible preferred stock of Vycor (see Note 11). As a result of this exchange, no future loan payments will be due on account of such convertible debt instruments.

Segment_Reporting_Geographical

Segment Reporting, Geographical Information	6 Months Ended
	Jun. 30, 2014
Segment Reporting, Geographical Information [Abstract]	'
SEGMENT REPORTING, GEOGRAPHICAL INFORMATION	'
	4.   SEGMENT REPORTING, GEOGRAPHICAL INFORMATION
	(a) Business segments
	The Company operates in two business segments: Vycor Medical, which focuses on devices for neurosurgery; and NovaVision, which focuses on neuro stimulation therapies and diagnostic devices for the treatment and screening of vision field loss and which includes Sight Science. Set out below are the revenues, gross profits and total assets for each segment.
		Three Months Ended June 30,				Six Months Ended June 30,
		2014		2013		2014			2013
	Revenue:
	Vycor Medical	$	203,191	$	146,358	$	466,902		$	277,024
	NovaVision		95,349	88,596		189,760			189,604
	Total Revenue	$	298,540	$	234,954	$	656,662		$	466,628
	Gross Profit:
	Vycor Medical	$	177,717	$	135,152	$	411,125		$	251,431
	NovaVision		85,056		71,908		166,813			157,285
	Total Gross Profit	$	262,773	$	207,060	$	577,938		$	408,716
		June 30,		December 31,
		2014		2013
	Total Assets:
	Vycor Medical	$	3,521,581	$	799,120
	NovaVision		1,271,097		1,316,130
	Total Assets	$	4,792,678	$	2,115,250
	(b) Geographic information
	The Company operates in two geographic segments, the United States and Europe. Set out below are the revenues, gross profits and total assets for each segment.
	531,635
		Three Months Ended June 30,				Six Months Ended June 30,
		2014		2013		2014			2013
	Revenue:
	United States	$	238,474	$	180,792	$		$	360,307
	Europe		60,066		54,162		125,027			106,321
	Total Revenue	$	298,540	$	234,954	$	656,662		$	466,628
	Gross Profit:
	United States	$	207,577	$	161,140	$	465,816		$	317,328
	Europe		55,196		45,920		112,122			91,388
	Total Gross Profit	$	262,773	$	207,060	$	577,938		$	408,716
		June 30,		December 31,
		2014		2013
	Total Assets:
	United States	$	4,322,406	$	1,604,142
	Europe		470,272		511,108
	Total Assets	$	4,792,678	$	2,115,250

Equity

Equity	6 Months Ended
	Jun. 30, 2014
Equity [Abstract]	'
EQUITY	'
	5.   EQUITY
	The Offering
	On January 2, January 31, February 28, March 31, and April 25, 2014 the Company completed five separate closings (the “Closings” of an offering (the “Offering”) of Units comprising shares of common stock (“Common Stock”) (collectively, the “Shares” and individually, a “Share”) and Series A and Series B Warrants (collectively, the “Warrants”) (collectively, the “Units”) to accredited investors (the “Investors”) in a private placement. The Closings comprised the sale of an aggregate of $5,000,000 in the Units), which were issued pursuant to five separate Securities Purchase Agreements between the Company and the Investors in each of the four Closings.  In the aggregate, the Company issued 2,777,808 shares of Common Stock, Series A Warrants to purchase an aggregate of 1,388,919 shares of Common Stock and Series B Warrants to purchase an aggregate of 1,388,919 shares of Common Stock.
	Each Unit was priced at $1.80 and comprised of one share of Common Stock, a Series A warrant (the “Series A Warrants”) and a series B warrant (the “Series B Warrants”). The Series A Warrants were detachable and were exercisable over a three-year term and were issued with respect to the purchase of a number of shares of Common Stock equal to 50% of the number of Shares purchased by such investor at an exercise price per share of $2.05.   The Series B Warrants were detachable and were exercisable over a three-year term and were issued with respect to the purchase of a number of shares of Common Stock equal to 50% of the number of Shares purchased by such investor at an exercise price per share of $3.08. The Warrants are subject to adjustment for stock splits, stock dividends or recapitalizations.
	Also on January 2, 2014, Fountainhead exchanged an aggregate of $1,426,542 of consulting fees owed to it by the Company for the Units issued in the Offering. In the aggregate, the Company issued to Fountainhead 792,523 shares of Common Stock, Series A Warrants to purchase an aggregate of 396,262 shares of Common Stock and Series B Warrants to purchase an aggregate of 396,262 shares of Common Stock.
	Based on the subscription terms applicable to the holders of the Company’s previously-issued Series C Convertible Preferred Stock, such holders were given the option of exchanging their investment in such unconverted Series C Convertible Preferred Stock and the related warrants into the securities which are the subject of the Offering, based on the amount of their investment in the Series C Convertible Preferred Stock and the related warrants.  On February 24, 2014, the holders of 15.15 shares of Series C Convertible Preferred Stock (representing an aggregate investment of $757,700) exchanged their Series C Convertible Preferred Stock and related warrants for an aggregate of 420,838 shares of Common Stock, Series A Warrants to purchase an aggregate of 210,419 shares of Common Stock and Series B Warrants to purchase an aggregate of 210,419 shares of Common Stock.
	Under the terms of the Placement Agent agreement with Garden State Securities, Inc. (“GSS”) (see Note 9), the Company issued an aggregate of 402,033 Placement Agent Warrants, on almost identical terms to the Series A Warrants.
	The Series A Warrants and Placement Agent Warrants carried anti-dilution rights (which arose in the event the Company sold securities at a price below $2.05 within one year of the date that the initial Registration Statement has been declared effective by the SEC). Effective May 15, 2014 these anti-dilution rights were waived for all but 34,723 of the Series A Warrants and for all of the Placement Agent Warrants.  Accordingly, 34,723 shares of Common Stock are subject to anti-dilution and are recorded as a derivative liability in accordance with the guidance contained in ASC 815-40-15-7D (see Note 2 and Note 7)
	Other Equity Transactions
	During January to June 2014, the Company issued: 4,516 shares of Common Stock (valued at $10,000) to Steven Girgenti, 4,238 shares of Common Stock (valued at $10,000) to Oscar Bronsther and 3,734 shares of Common Stock (valued at $8,750) to Lowell Rush in consideration for services provided to the Board of Directors; and 1,437 shares of Common Stock (valued at $3,125) to Alvaro Pasual-Leone, 2,873 shares of Common Stock (valued at $6,250) to Josef Zihl and 1,324 shares of Common Stock (valued at $3,125) to each of Jason Barton and Jose Romano in respect of their roles as members of the NovaVision, Inc. Scientific Advisory Board.
	During January to June 2014, in accordance with the terms the Consulting Agreement, the Company issued 12,605 shares of Common Stock (valued at $30,000) to Fountainhead.
	During January 2014, the Company issued 3,000 and 2,000 shares of Common Stock (valued at $5,400 and $3,600) to Del Mar Consulting Group, LLC and Alex Partners respectively under the terms of their advisory amendment agreements.
	On March 11, 2014 the Company entered into an Amendment Agreement with GSS. Under the Amendment Agreement, the Company agreed to issue 30,000 shares of Common Stock (valued at $66,000) on the date of the Amendment Agreement in respect of the period January to June 2014, rather than 7,500 shares per month under the original agreement.
	During March 2014, in accordance with the terms of an investor relations advisory agreement, the Company issued 2,500 shares of Common Stock (valued at $4,700) to J and M Group, LLC.
	During June 2014, in accordance with the terms of an investor relations advisory agreement, the Company issued 18,000 shares of Common Stock (valued at $43,020) to Hayden IR, LLC.

ShareBased_Compensation

Share-Based Compensation	6 Months Ended
	Jun. 30, 2014
Share-Based Compensation [Abstract]	'
SHARE-BASED COMPENSATION	'
	6.   SHARE-BASED COMPENSATION
	Stock Option Plan
	The Company adopted the Vycor Medical, Inc Employee, Director, and Consultant Stock Plan (the “Plan”) as of February 13, 2008.  The Plan provides for both incentive stock options and nonqualified stock options to be granted to employees, officers, consultants, independent contractors, directors and affiliates of the Company.   The board of directors establishes the terms and conditions of all stock option grants, subject to the Plan and applicable provisions of the Internal Revenue Code.  Incentive stock options must be granted at an exercise price not less than the fair market value of the common stock on the grant date.  The options granted to participants owning more than 10% of the Company’s outstanding voting stock must be granted at an exercise price not less than 110% of the fair market value of the common stock on the grant date.  The options expire on the date determined by the board of directors, but may not extend mare than 10 years from the grant date, while incentive stock options granted to participants owning more than 10% of the Company’s outstanding voting stock expire five years from the grant date. The vesting period for employees is generally over three years.  The vesting Period for non-employees is determined based on the services being provided. The maximum number of shares of stock which may be delivered under the plan shall automatically increase by a number sufficient to cause the number of shares covered by the plan to equal 10% of the total number of shares of stock then outstanding on a fully diluted basis.
	Under ASC Topic 718, the Company estimates the fair value of option awards on the date of grant using an option pricing model. The grant date fair value is recognized over the option vesting period, the period during which an empoyee is required to provide service in exchange for the award. No compensation cost is recognized for equity instruments for which employees do not render the requisite service. Under these standards, compensation cost for employee cost for employee stock-based awards is based on the estimated grant-date fair value and recognized over the vesting period of the applicable award on a straight-line basis.  No employee stock options were granted for the three and six month periods ended June 30, 2014 and 2013.
	Initial grants of options to purchase 500,000 shares were issued under the Plan on February 13, 2008 to each of Kenneth T. Coviello, the Company’s then Chief Executive Officer and then Heather N. Vinas, the Company’s President at an exercise price of $0.135 per share.  The options vested 33-1/3% on each of the first, second, and third anniversary of the grant and expire February 12, 2018. Following Heather Vinas’ resignation as President of the Company in May 2010, 166,667 unvested options were cancelled. These options have been fully expensed.
	Stock appreciation rights may be granted either on a stand alone basis or in conjunction with all or part of any other stock options granted under the plan.  As of June 30, 2014 there were no awards of any stock appreciation rights.
	The Company from time to time issues common stock, stock options or common stock warrants to acquire services or goods from non-employees. Common stock, stock options and common stock warrants issued to other than employees or directors are recorded on the basis of their fair value, which is measured as of the “measurement date” using an option pricing model. The “measurement date” for options and warrants related to contracts that have substantial disincentives to non-performance is the date of the contract, and for all other contracts is the vesting date. Expense related to the options and warrants is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant.
	The details of the outstanding rights, options and warrants and value of such rights, options and warrants are as follows:
	STOCK WARRANTS:	Number of			Weighted average
		shares			exercise price
					per share
	Outstanding at December 31, 2012		1,749,874		$	3.03
	Granted		—			—
	Exercised		(341,941	)		1.49
	Cancelled or expired		(3,334	)		10.5
	Outstanding at December 31, 2013		1,404,599		$	3.39
	Granted		4,404,401			2.52
	Exercised		—			—
	Cancelled or expired		(582,477	)		4.45
	Outstanding at June 30, 2014		5,226,523		$	2.54
	STOCK OPTIONS:		Number of			Weighted average
			shares			exercise price
						per share
	Outstanding at December 31, 2012		5,557		$	20.25
	Granted		—			—
	Exercised		—			—
	Cancelled or expired		—			—
	Outstanding at December 31, 2013		5,557		$	20.25
	Granted		—			—
	Exercised		—			—
	Cancelled or expired		—			—
	Outstanding at June 30, 2014		5,557		$	20.25
	As of June 30, 2014, the weighted-average remaining contractual life of outstanding warrants and options is 2.33 and 3.63 years, respectively.
	Non-Employee Stock Compensation
	During the six months ended June 30, 2014, the Company issued an aggregate of 4,516 shares of Common Stock (valued at $10,000) to Steven Girgenti, 4,238 shares of Common Stock (valued at $10,000) to Oscar Bronsther and 3,734 shares of Common Stock (valued at $8,750) to Lowell Rush for services rendered to the board of directors. For the six months ended June 30, 2014, a total of $28,750 was recognized as share-based compensation for the issuance of these shares.
	During six months ended June 30, 2014 the Company issued an aggregate of 1,437, 1,324 and 1,324 shares of common stock, respectively, valued at $3,125, to each of Alvaro Pascual-Leone, Jason Barton and Jose Romano and 2,873 shares of common stock valued at $6,250 to Josef Zihl for services rendered to the Scientific Advisory Board of NovaVision. For the six months ended June 30, 2014, an aggregate of $15,625 was recognized as share-based compensation for the issuance of these shares.
	In November 2013, the Company entered into three-month extension amendments to the existing agreements with Del Mar Consulting, Inc. and Alex Partners, LLC under which 33,000 and 27,000 shares of Company Common Stock respectively were issued, valued at $66,000 and $54,000 respectively. The value of these shares was amortized over the period of the agreement, and for the six months ended June 30, 2014 stock compensation of $78,620 was recognized as share-based compensation in connection with these agreements. Under the extension agreement, the Company has the option to pay all or part of the monthly fees in cash and for January 2014 3,000 shares valued at $5,400 were issued to Del Mar and 2,000 shares valued at $3,600 were issued to Alex Partners.
	On July 2, 2013, the Company entered into an advisory agreement, amended March 11, 2014 with Garden State Securities, Inc.(“GSS”) to provide certain financial advisory services to the Company. Under the terms of the advisory agreement, the Company issued 30,000 restricted shares of Company Common Stock to GSS in March 2014 valued at $66,000, which is being amortized over the six months from January 1, 2014, being the remaining term of the agreement. For the six months ended June 30, 2014 stock compensation of $66,000 was recognized as share-based compensation in connection with this agreement.
	On January 2, 2014 the Company issued warrants to Dr. Donald O’Rourke to purchase 7,000 shares of Vycor Common Stock at an exercise price of $3.08 per share, exercisable for a period of three years. The fair value of these warrants was estimated at $5,522 using Black-Scholes and the full value was recognized immediately.
	On January 2, 2014 the Company and Fountainhead amended their Consulting Agreement. Under the Amendment, 12,605 shares valued at $30,000 were issued to Fountainhead in respect of fees for the six months ended June 30, 2014.
	In March 2014, the Company entered into a one-month investor relations advisory agreement with J and M Group, LLC, under which the Company issued 2,500 shares of Common Stock valued at $4,700, which was fully expensed in March 2014.
	In March 2014, the Company entered into an investor relations advisory agreement with Hayden IR, LLC, under which the Company issued 18,000 shares of Common Stock valued at $43,020, which is being amortized over the six months from April to September, 2014. For the six months ended June 30, 2014 stock compensation of $21,510 was recognized as share-based compensation in connection with this agreement.
	Aggregate stock-based compensation expense charged to operations for stock and warrants granted to the above non-employees for the six months ended June 30, 2014 was $259,727. As of June 30, 2014, there was $21,510 of total unrecognized compensation costs related to warrant and stock awards and non-vested options.
	Stock-based compensation expenses related to employee options and warrants granted to non-employees are recognized as the stock options and warrants are earned. The stock options or warrants meet the criteria for equity treatment and the fair value of the stock options or warrants granted is estimated at the grant date and the expense is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant.  The grant date fair value of employee share options and similar instruments is estimated using the Black-Scholes option pricing model on the basis of the fair value of the underlying common stock on the measurement date, using the assumptions noted in the table below. The fair value of the common stock is determined by the then-prevailing share price. Expected volatility is based on the historical volatility of a peer group of publicly traded companies.
	The following assumptions were used in calculations of the Black-Scholes option pricing model for the six months ended June 30, 2014 and 2013:
		Six months ended June 30,
		2014			2013
	Risk-free interest rates		0.78	%		—
	Expected life		3 years			—
	Expected dividends		0	%		—
	Expected volatility		75	%		—
	Vycor Common Stock fair value	$	2.05			—

Fair_Value_Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2014
Fair Value Measurements [Abstract]	'
FAIR VALUE MEASUREMENTS	'
	7.   FAIR VALUE MEASUREMENTS
	The Company has adopted ASC 820 for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period. The adoption of ASC 820 did not have an impact on the Company’s financial position or results of operations.
	Under the terms of the Offering, during the period January 2 to April 25, 2014, in five separate closings, a total of 2,397,631 Series A Warrants and Placement Agent Warrants were issued as part of the Offering, which carried anti-dilution rights. Effective May 15, 2014 these anti-dilution rights were waived for all but 34,723 of the Series A Warrants and for all of the Placement Agent Warrants.  The Company accounts for the Series A Warrants and Placement Agent Warrants in accordance with the guidance contained in ASC 815-40-15-7D, whereby under that provision, because they have anti-dilution rights, they do not meet the criteria for equity treatment and must be recorded as a liability. Accordingly, the Company classifies the warrant instrument as a liability at its fair value and adjusts the instrument to fair value at each reporting period.
	The following table presents information about the Company’s liabilities that are measured at fair value on a recurring basis (the Series A Warrants described above) as of June 30, 2014 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical liabilities. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs are unobservable data points for the liability, and includes situations where there is little, if any, market activity for the liability :
	Description		June 30,			Level 1		Level 2		Level 3
			2014
	Warrant Liability	$	37,152		$	—	$	—	$	37,152
	The table below provides a reconciliation of the beginning and ending balances for the liabilities measured using fair significant unobservable inputs (Level 3):
	Balance at December 31, 2013	$	—
	Issuance of Series A Warrants and Placement Agent Warrants as part of Offering Units on January 2, January 31, February 24, February 28 and March 31, April 25, 2014		2,103,195
	Change in fair value during period		269,993
	Reduction in liability from waiver of anti-dilution May 15, 2014		(2,336,036	)
	Balance at June 30, 2014	$	37,152
	The fair value of the Series A Warrants and Placement Agent Warrants was determined using a Monte Carlo Simulation. This model requires the input of highly subjective assumptions, including the expected price volatility, which is based on the historical volatility of a peer group of publicly traded companies. Changes in the subjective input assumptions can materially affect the estimate of fair value of the warrants and the Company’s results of operations could be impacted.
	The following assumptions were used in calculations of the Monte Carlo Simulation model for the six months ended June 30, 2014 and 2013:
		Six months ended June 30,
		2014			2013
	Risk-free interest rates		0.68-0.93%			—
	Expected life		3 years			—
	Expected dividends		0%			—
	Expected volatility		71-97%			—
	Vycor Common Stock fair value		$1.88-$2.70			—

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	8.   COMMITMENTS AND CONTINGENCIES
	Lease
	The Company leases approximately 10,000 sq. ft located at 6401 Congress Ave., Suite 140, Boca Raton, FL 33487 from Catexor Limited Partnership for a gross rent of $14,260 plus sales tax per month.  The term of the lease is 5 years and 6 months terminating July, 2017. The Company’s subsidiaries in Germany and the UK occupy properties on short term lease agreements. Rent expense for the six months ended June 30, 2014 and 2013 were $99,160 and $96,444 respectively.
	Potential German tax liability
	In June 2012 the Company's German subsidiary received a preliminary assessment for Magdeburg City trade tax of approximately €75,000 (approximately $94,000). This assessment is for the 2010 fiscal year and relates to the Company's acquisition of the assets of the former NovaVision, Inc. An initial assessment for corporate tax for the same period has been preliminarily reduced to zero. The Company has not accepted this trade tax assessment and is in discussion with the relevant tax authorities with a view to its reduction. The tax authorities have agreed to suspend the assessment pending the outcome of certain court hearings, and the Company has agreed to make limited monthly payments on account. To the extent that this assessment, a higher or a reduced amount, is ultimately confirmed by the tax authorities, the Company believes it has a very strong claim against certain professional advisors which would offset the liability in full. Accordingly, the Company has made no provision for this liability for the six months ending June 30, 2014, other than recording the monthly payments as an expense.
	Potential Patent Infringement
	The Company was made aware in 2012 that a competitor had been granted a patent for related technology, and appeared to be entering the market with products that infringe the Company’s own issued patent. Following investigation, the Company has taken steps to initiate an invalidation of the competitor’s patent and enforce its patent rights; in March 2014 the Patent Re-examination Board issued an Examination Decision invalidating all the claims of the competitor’s patent. The competitor has the right of appeal but the Company will contest any such appeal. The Company has also been made aware that a second competitor has filed a patent application for related technology and also may be producing a product that potentially infringes the Company’s patent, and is in the early stages of evaluation and has yet to determine what, if any actions to take in this instance, however as a general rule the Company intends to take all necessary action to protect its patent portfolio. As with all patent infringement actions, there is some risk that the accused infringer will not be found to infringe the claims, and an additional risk that the accused infringer will successfully challenge the validity of the asserted claims.

Consulting_and_Other_Agreement

Consulting and Other Agreements	6 Months Ended
	Jun. 30, 2014
Consulting and Other Agreements [Abstract]	'
CONSULTING AND OTHER AGREEMENTS	'
	9. CONSULTING AND OTHER AGREEMENTS
	The Company has entered into no new consulting or other agreements during the six months ended June 30, 2014, other than amendments to existing agreements outlined below. The following agreements remained in force during the period:
	Consulting Agreement with Fountainhead
	Effective as of January 2, 2014, the Company and Fountainhead amended their Consulting Agreement to extend the term of the Consulting Agreement to January 2, 2015.  As of January 2014, the monthly retainer payable to Fountainhead was reduced to $10,000 per month, payable $5,000 in cash and the remainder payable in Company Common Stock at the end of each quarter until the occurrence of specified milestones.
	Consulting Agreement with Del Mar Consulting Group, Inc and Alex Partners, LLC.
	In November 2013, the Company entered into three-month extension amendments to the existing agreements with Del Mar Consulting, Inc. and Alex Partners, LLC under which 33,000 and 27,000 shares of Company Common Stock respectively were issued, valued at $66,000 and $54,000 respectively. These agreements expired at the end of February 2014.
	Garden State Securites, Inc. (“GSS”) Advisory and Placement Agent Agreements
	On July 2, 2013, the Company entered into two agreements with GSS one to provide certain financial advisory services to the Company (“Advisory Agreement”) and the other to act as placement agent for the Company (“Placement Agent Agreement”).
	Under the terms of the Advisory Agreement, GSS is engaged on a non-exclusive basis to provide financial advisory services to the Company for at least ninety (90) days and thereafter until either party terminates the arrangement.  Under the terms of the Advisory Agreement, as amended on March 14, 2014, the Company will issue 45,000 restricted shares of Company Common Stock to the broker-dealer, 15,000 of which are issuable on the date of the execution of the Agreement and 30,000 additional shares to be issued on March 11, 2014.  The Agreement also calls for the Company to reimburse certain out-of-pocket expenses.
	Under the terms of the Placement Agent Agreement, the Company engaged GSS as its exclusive placement agent until the later of (i) 90 days from the date of execution of the Agreement or (ii) the end of the offering period of any securities financing undertaken by the Company in connection with the Placement Agent Agreement. Normal placement agents fees and expense reimbursement will be payable. Any offering will be undertaken on a “best efforts” basis and the proceeds would be used for working capital and general corporate purposes
	Hayden IR, LLC. Investor Relations Agreement
	In March 2014, the Company entered into a twelve (12) month investor relations advisory agreement, as amended (“Hayden Agreements”) in June 2014, with Hayden IR, LLC.  Under the terms of Hayden Agreements, Hayden receives $8,500 in cash per month and 36,000 shares of Common Stock; 18,000 issued in June 2014 and 18,000 to be issued on September 30, 2014.

Related_Party_Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2014
Related Party Transactions [Abstract]	'
RELATED PARTY TRANSACTIONS	'
	10.  RELATED PARTY TRANSACTIONS
	Under the terms of the Offering, there were certain agreements with Related Parties:
	(a)
	Debt Amendment and Repayment.   Fountainhead and Peter Zachariou agreed to extend the maturity of all of the Company’s debt obligations due to them due to as of August 9, 2013 (aggregating $2,247,037) to January 2, 2017, subject to the earlier repayment of such debt upon the occurrence of certain specified conditions.  Fountainhead and Peter Zachariou further released all security interests associated with any of the obligations and agreed to forebear declaring any event of default under the obligations for a period of 24 months following the date of the Initial Closing. During January and February 2014, also under the terms of the Offering, debt obligations arising since August 9, 2013 were repaid as follows: Fountainhead - $91,519; Peter Zachariou - $20,000; David Cantor - $15,000.
	(b)
	Employment of Chief Executive Officer and Employment Agreements.  Effective as of January 2, 2014, our board of directors appointed Peter C. Zachariou, our Executive Vice President, to the additional role as the Company’s Chief Executive Officer. Also effective as of the January 2, 2014 the Company entered into separate, but largely identical Employment Agreements with Mr. Zachariou, Adrian Liddell and David Cantor. Mr. Zachariou’s Employment Agreement commences on the Effective Date and terminates six months following the appointment of a successor Chief Executive Officer; Mr. Liddell’s Employment Agreement commences on the Effective Date and terminates upon the appointment of a successor Chief Financial Officer; and Mr. Cantor’s Employment Agreement commences on the Effective Date and terminates upon the appointment of a successor. The aforementioned Employment Agreements provide for annual compensation of $110,000, payment of which is deferred for 12 months from the Effective Date and is subject to the achievement of certain enumerated milestone conditions. Each of these Employment Agreements supersede any prior employment agreements or arrangements between the respective parties.
	(c)
	Amendment to Consulting Agreement.  Effective as of January 2, 2014, the Company and Fountainhead amended their Consulting Agreement to extend the term of the Consulting Agreement to to January 2, 2015.  As of January 2014, the monthly retainer payable to Fountainhead was reduced to $10,000 per month, payable $5,000 in cash and the remainder payable in Company Common Stock at the end of each quarter until the occurrence of specified milestones.
	(d)
	Conversion Agreement.  Effective as of January 2, 2014, the Company and Fountainhead entered into a Conversion Agreement whereby Fountainhead agreed to convert all amounts accrued as of the date of the Initial Closing into an investment in that amount in the Offering.  Pursuant to the terms of this agreement, Fountainhead converted $1,426,542 of accrued consulting fees into the Units.
	During January to June 2014, in accordance with the terms the Consulting Agreement, the Company issued 12,605 shares of Common Stock (valued at $30,000) to Fountainhead.
	During June 2014 related party accrued interest due payments were made to: Fountainhead ($202,683); Peter Zachariou, a director of the Company ($69,198); and David Cantor, a director of the Company ($247).
	There were no other related party transactions during the six months ended June 30, 2014 other than the payment or accrual of fees under the Fountainhead Consulting agreement described in Note 10 of the financial statements.

Subsequent_Events

Subsequent Events	6 Months Ended
	Jun. 30, 2014
Subsequent Events [Abstract]	'
SUBSEQUENT EVENTS	'
	11.  SUBSEQUENT EVENTS
	The Company evaluated subsequent events through the date the financial statements were issued:
	Share Issuance
	During July and August 2014, the Company issued 2,016 shares of Common Stock (valued at $5,000) to Steven Girgenti, in consideration for services provided to the Board of Directors; and 570 and 1,141 shares of Common Stock respectively (valued at $1,563 and $3,125 respectively) to Alvaro Pascual-Leone and Josef Zihl in respect of their roles as members of the NovaVision, Inc. Scientific Advisory Board.
	Debt Extinguishment and conversion to Preferred
	On August 5, 2014 Fountainhead, along with certain other related and non-related parties (together, the “Fountainhead Parties”), exchanged all their $2,355,587 of debt into an equivalent amount of preferred equity in the Company. This equity exchange will result in Vycor’s Shareholders’ Equity being increased by $2,355,587, equivalent to the current debt. Under the terms of the exchange, the Fountainhead Parties will receive $2,355,587 of Vycor Series D preferred shares (“Series D”) that will be convertible into Vycor Shares at a price of $2.15. The Series D will carry a dividend of 7% per annum, payable in cash or Series D at the Company’s option, rising to 12% payable in cash after two years. The Company is able to redeem the Series D at par at any time, at its sole option. The Fountainhead Parties will also receive 3-year warrants equivalent to 75% of the Vycor Shares received in the exchange on a converted basis, exercisable at $3.08. After three years, if the Series E has not then been redeemed or converted, the Fountainhead Parties will receive additional warrants equivalent to 50% of the shares then held, exercisable at the then market price.
	Also on August 5, 2014, in a transaction not related to the exchange, Fountainhead entered into an agreement with the Company preventing it from selling any Vycor Shares currently held by Fountainhead below $4.50. In return, the Company agreed to extend the life of certain of Fountainhead’s existing warrants expiring in 2015 to the same 3-year term as the warrants being issued under the exchange.

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2014
Significant Accounting Policies [Abstract]	'
Principles of Consolidation	'
	Principles of Consolidation
	The consolidated financial statements include the accounts of Vycor Medical, Inc., and its wholly-owned subsidiaries, NovaVision, Inc. (a Delaware corporation), NovaVision GmbH (a German corporation) and Sight Science Limited (a UK corporation), both wholly owned subsidiaries of NovaVision, Inc. The Company is headquartered in Boca Raton, FL. All material inter-company accounts, transactions, and profits have been eliminated in consolidation.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	From time to time new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations and cash flows when implemented.
Derivative Liability	'
	Derivative Liability
	The Company accounts for the 34,723 Series A Warrants issued in connection with the Offering (all as defined in Note 5), the holders of which have not waived their anti-dilution rights (as detailed further in Note 5) in accordance with the guidance contained in ASC 815-40-15-7D, whereby under that provision, because they have anti-dilution rights, they do not meet the criteria for equity treatment and must be recorded as a liability. Accordingly, the Company classifies the warrant instrument as a liability at its fair value and adjusts the instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised or until the anti-dilution provisions contained within the warrant agreements expire, and is classified in the balance sheet as a current liability. Any change in fair value of the warrant liability is recognized in the Company’s statement of operations as other income (loss).
Software Development Costs	'
	Software Development Costs
	The authoritative accounting guidance requires software development costs to be capitalized upon completion of the preliminary project stage.  Accordingly, direct internal and external costs associated with the development of the features and functionality of the Company’s software, incurred during the application development stage, are capitalized and amortized using the straight-line method of the estimated life of five years once the software has been brought into service. Capitalized software development costs for the six months ended June 30, 2014 and 2013 were $55,039 and $0, respectively. During the period the Company’s VRT 7.0 program completed the preliminary project stage, following which there was a capitalization of $25,199 of software development costs. Additional costs of $21,463 were capitalized for the Company’s NeuroEyeCoach program (prior to being brought into service in March 2014 with a total capitalized value of $119,106), and $8,377 for a NeuroEyeCoach retail/physician model.
Net Loss Per Share	'
	Net Loss Per Share
	Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Dilutive potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock and convertible debt.  Such potentially dilutive shares are excluded when the effect would be to reduce a net loss
	per share. No dilution adjustment has been made to the weighted average outstanding common shares in the periods presented because the assumed exercise of outstanding options and warrants and the conversion of preferred stock and debt would be anti-dilutive.
	The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share:
		June 30,		June 30,
		2014		2013
	Stock options outstanding		5,557		5,557
	Warrants to purchase common stock		5,226,523		1,423,123
	Debentures convertible into common stock		477,716		368,727
	Preferred shares convertible into common stock		14,815		320,007
	Total		5,724,611		2,117,414

Significant_Accounting_Policie2

Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2014
Significant Accounting Policies [Abstract]	'
Potential shares of common stock that are not included in the calculation of diluted net loss per share	'
		June 30,		June 30,
		2014		2013
	Stock options outstanding		5,557		5,557
	Warrants to purchase common stock		5,226,523		1,423,123
	Debentures convertible into common stock		477,716		368,727
	Preferred shares convertible into common stock		14,815		320,007
	Total		5,724,611		2,117,414

Notes_Payable_Tables

Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2014
Notes Payable [Abstract]	'
Components of notes payable	'
				June 30,				December 31,
				2014				2013
	On December 29, 2009 and February 3, 2010, the Company issued convertible debentures in the amount of $371,362 and $70,000, respectively, payable to Fountainhead Capital Management (“Fountainhead”), the beneficial owner of more than 50% of the Company’s common stock. These debentures accrue interest at a rate of 6% per annum. The Holder is entitled to convert all or any amount of the principal face amount of the debentures then outstanding into shares of common stock of the Company at the conversion price of $1.88 per share, subject to adjustment, and does not require bifurcation. These debentures were originally due August 31, 2010 and the due date has been extended to January 2, 2017, subject to certain early repayment provisions. (On August 5, 2014 the holder agreed to exchange the note into series D convertible preferred stock of Vycor, see Note 11)			441,362				441,362
				June 30,				December 31,
				2014				2013
	On March 31, 2010 and October 14, 2010, the Company issued convertible debentures payable to Fountainhead in the amount of $85,000 and $90,000, respectively. These debentures accrue interest at a rate of 6%. The Holder is entitled to convert all or any amount of the principal face amount of the debentures then outstanding into shares of common stock of the Company at the conversion price of $2.63 per share, subject to adjustment and does not require bifurcation. The debentures were originally due August 31, 2011, and the due date has been extended to January 2, 2017, subject to certain early repayment provisions. (On August 5, 2014 the holder agreed to exchange the note into series D convertible preferred stock of Vycor, see Note 11)			175,000				175,000
	On October 26, 2010 and November 15, 2010, the Company issued debentures payable to Fountainhead in the amount of $77,500 and $322,500, respectively. These debentures accrue interest at a rate of 6% per annum. These debentures were originally due August 31, 2011 and the due date has been extended to January 2, 2017, subject to certain early repayment provisions. (On August 5, 2014 the holder agreed to exchange the note into series D convertible preferred stock of Vycor, see Note 11)			400,000				400,000
	On November 15, 2010, the Company issued a convertible debenture in the amount of $350,000 payable to Peter Zachariou, a Director of the Company. This debenture accrues interest rate of 6% per annum. The Holder is entitled to convert all or any amount of the principal face amount of the debenture then outstanding into shares of common stock of the Company at the conversion price of $2.85 per share, subject to adjustment and does not require bifurcation. On December 20, 2010, the Company repaid $50,000 of this debenture and removed the convertible rights. The debentures were originally due December 31, 2012 and the due date has been extended   to January 2, 2017, subject to certain early repayment provisions. (On August 5, 2014 the holder agreed to exchange the note into series D convertible preferred stock of Vycor, see Note 11)			300,000				300,000
	In the period July to December 2012 the Company issued short term, unsecured notes payable to Fountainhead in the aggregate amount of $300,900. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. The due date has been extended  to January 2, 2017, subject to certain early repayment provisions. (On August 5, 2014 the holder agreed to exchange the note into series D convertible preferred stock of Vycor, see Note 11)			300,900				300,900
	In the period August to December 2012 the Company issued short term, unsecured notes payable to Peter Zachariou in the aggregate amount of $115,550. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. The due date has been extended  to January 2, 2017, subject to certain early repayment provisions. (On August 5, 2014 the holder agreed to exchange the note into series D convertible preferred stock of Vycor, see Note 11)			115,550				115,550
	In the period January to September 2013 the Company issued short term, unsecured notes payable to Fountainhead in the aggregate amount of $325,744. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. The due date has been extended  to January 2, 2017, subject to certain early repayment provisions (On August 5, 2014 the holder agreed to exchange the note into series D convertible preferred stock of Vycor, see Note 11)			324,225				324,225
				June 30,				December 31,
				2014				2013
	In the period August 9 to December 2013 the Company issued short term, unsecured notes payable to Fountainhead in the aggregate amount of $91,519. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. These notes were repaid in January and February 2014.			—				91,519
	In the period January to September 2013 the Company issued short term, unsecured notes payable to Peter Zachariou in the aggregate amount of $210,000. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. The due date has been extended  to January 2, 2017, subject to certain early repayment provisions. (On August 5, 2014 the holder agreed to exchange the note into series D convertible preferred stock of Vycor, see Note 11)			190,000				190,000
	In the period August 9 to December 2013 the Company issued short term, unsecured notes payable to Peter Zachariou in the aggregate amount of $20,000. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. This note was repaid in February 2014			—				20,000
	In the period August 9 to December 2013 the Company issued short term, unsecured notes payable to David Cantor, in the aggregate amount of $15,000. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. This note was repaid in 2014.			—				15,000
	Total Related Party Notes Payable:		$	2,247,037			$	2,373,556
				June 30,				December 31,
				2014				2013
	On March 25, 2011 the Company issued a term note for $300,000 to EuroAmerican Investment Corp. (“EuroAmerican”). The term note bears interest at 16% per annum and was due June 25, 2011. In connection with the loan the Company also issued EuroAmerican warrants to purchase 400,000 shares of the Company’s common stock at an exercise price of $4.50 per share for a period of three (3) years. On June 25, 2011 the due date for this note was extended to September 25, 2011 and the Holder was granted the right to convert all or any amount of the principal face amount of the debenture then outstanding and accrued interest into shares of common stock of the Company an adjusted  conversion price of $1.80 per share, subject to adjustment and does not require bifurcation. The due date for this note has been extended to January 2, 2015, subject to certain early repayment provisions.			300,000				300,000
				June 30,				December 31,
				2014				2013
	In the period August to December 2012 the Company issued short term, unsecured notes payable to Craig Kirsch in the aggregate amount of $98,550. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. The due date for this note has been extended  to January 2, 2017, subject to certain early repayment provisions. (On August 5, 2014 the holder agreed to exchange the note into series D convertible preferred stock of Vycor, see Note 11)			98,550				98,550
	In September 2012 the Company issued short term, unsecured notes payable to Osbaldo Trading Limited in the amount of $42,900. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. This note was repaid in June 2014.			—				42,900
	In the period June to September 2013 the Company issued short term, unsecured notes payable to Craig Kirsch in the aggregate amount of $10,000. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. The due date for this note has been extended  to January 2, 2017, subject to certain early repayment provisions.(On August 5, 2014 the holder agreed to exchange the note into series D convertible preferred stock of Vycor, see Note 11)			10,000				10,000
	In the period August 9 to December 2013 the Company issued short term, unsecured notes payable to Craig Kirsch in the aggregate amount of $3,000. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. This note was repaid in February 2014.			—				3,000
	On October 22, 2013 the Company issued a term note for $100,000 to EuroAmerican Investment Corp. (“EuroAmerican”). The term note bears interest at 16% per annum and was due November 30, 2013. This note was repaid in January 2014.			—				100,000
	Insurance policy finance agreements. During the six months ended June 30, 2014 the Company received proceeds from Insurance policy finance agreements of $28,525 and made repayments of $40,816			11,445				23,736
	Total Other Notes Payable:		$	419,995			$	578,186
Schedule of future minimum loan repayments	'
		Six months ending June 30				Related Party				Other
		2014				—				311,445
		2015				—				—
		2016				—				—
		2017				2,247,037				108,550
					$	2,247,037			$	419,995

Segment_Reporting_Geographical1

Segment Reporting, Geographical Information (Tables)	6 Months Ended
	Jun. 30, 2014
Segment Reporting, Geographical Information [Abstract]	'
Business segments information	'
			Three Months Ended June 30,					Six Months Ended June 30,
			2014		2013			2014		2013
	Revenue:
	Vycor Medical		$	203,191	$	146,358		$	466,902	$	277,024
	NovaVision			95,349		88,596			189,760		189,604
	Total Revenue		$	298,540	$	234,954		$	656,662	$	466,628
	Gross Profit:
	Vycor Medical		$	177,717	$	135,152		$	411,125	$	251,431
	NovaVision			85,056		71,908			166,813		157,285
	Total Gross Profit		$	262,773	$	207,060		$	577,938	$	408,716
			June 30,		December 31,
			2014		2013
	Total Assets:
	Vycor Medical		$	3,521,581	$	799,120
	NovaVision			1,271,097		1,316,130
	Total Assets		$	4,792,678	$	2,115,250
Summary of geographic information	'
		Three Months Ended June 30,					Six Months Ended June 30,
			2014		2013			2014		2013
	Revenue:
	United States		$	238,474	$	180,792		$	531,635	$	360,307
	Europe			60,066		54,162			125,027		106,321
	Total Revenue		$	298,540	$	234,954		$	656,662	$	466,628
	Gross Profit:
	United States		$	207,577	$	161,140		$	465,816	$	317,328
	Europe			55,196		45,920			112,122		91,388
	Total Gross Profit		$	262,773	$	207,060		$	577,938	$	408,716
			June 30,		December 31,
			2014		2013
	Total Assets:
	United States		$	4,322,406	$	1,604,142
	Europe			470,272		511,108
	Total Assets		$	4,792,678	$	2,115,250

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2014
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]	'
Shedule of the outstanding rights, options and warrants and value of such rights, options and warrants	'
	STOCK WARRANTS:		Number of			Weighted average
			shares			exercise price
						per share
	Outstanding at December 31, 2012			1,749,874		$	3.03
	Granted			—			—
	Exercised			(341,941	)		1.49
	Cancelled or expired			(3,334	)		10.5
	Outstanding at December 31, 2013			1,404,599		$	3.39
	Granted			4,404,401			2.52
	Exercised			—			—
	Cancelled or expired			(582,477	)		4.45
	Outstanding at June 30, 2014			5,226,523		$	2.54
	STOCK OPTIONS:			Number of			Weighted average
				shares			exercise price
							per share
	Outstanding at December 31, 2012			5,557		$	20.25
	Granted			—			—
	Exercised			—			—
	Cancelled or expired			—			—
	Outstanding at December 31, 2013			5,557		$	20.25
	Granted			—			—
	Exercised			—			—
	Cancelled or expired			—			—
	Outstanding at June 30, 2014			5,557		$	20.25
Assumptions used in calculations of the Black-Scholes option pricing model for options and warrants	'
		Six months ended June 30,
			2014			2013
	Risk-free interest rates			0.68-0.93%			—
	Expected life			3 years			—
	Expected dividends			0%			—
	Expected volatility			71-97%			—
	Vycor Common Stock fair value			$1.88-$2.70			—
Stock options [Member]	'
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]	'
Assumptions used in calculations of the Black-Scholes option pricing model for options and warrants	'
		Six months ended June 30,
			2014			2013
	Risk-free interest rates			0.78	%		—
	Expected life			3 years			—
	Expected dividends			0	%		—
	Expected volatility			75	%		—
	Vycor Common Stock fair value		$	2.05			—

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Measurements [Abstract]	'
Schedule liabilities measured at fair value on a recurring basis	'
	Description			June 30,			Level 1		Level 2		Level 3
				2014
	Warrant Liability		$	37,152		$	—	$	—	$	37,152
Schedule of liabilities measured using fair significant unobservable inputs (Level 3)	'
	Balance at December 31, 2013		$	—
	Issuance of Series A Warrants and Placement Agent Warrants as part of Offering Units on January 2, January 31, February 24, February 28 and March 31, April 25, 2014			2,103,195
	Change in fair value during period			269,993
	Reduction in liability from waiver of anti-dilution May 15, 2014			(2,336,036	)
	Balance at June 30, 2014		$	37,152
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
		Six months ended June 30,
			2014			2013
	Risk-free interest rates			0.68-0.93%			—
	Expected life			3 years			—
	Expected dividends			0%			—
	Expected volatility			71-97%			—
	Vycor Common Stock fair value			$1.88-$2.70			—

Significant_Accounting_Policie3

Significant Accounting Policies (Details)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Potential shares of common stock that are not included in the calculation of diluted net loss per share	'	'
Potential shares of common stock that are not included in the calculation of diluted net loss per share	5,724,611	2,117,414
Stock options outstanding [Member]	'	'
Potential shares of common stock that are not included in the calculation of diluted net loss per share	'	'
Potential shares of common stock that are not included in the calculation of diluted net loss per share	5,557	5,557
Warrants to purchase common stock [Member]	'	'
Potential shares of common stock that are not included in the calculation of diluted net loss per share	'	'
Potential shares of common stock that are not included in the calculation of diluted net loss per share	5,226,523	1,423,123
Debentures convertible into common stock [Member]	'	'
Potential shares of common stock that are not included in the calculation of diluted net loss per share	'	'
Potential shares of common stock that are not included in the calculation of diluted net loss per share	477,716	368,727
Preferred shares convertible into common stock [Member]	'	'
Potential shares of common stock that are not included in the calculation of diluted net loss per share	'	'
Potential shares of common stock that are not included in the calculation of diluted net loss per share	14,815	320,007

Significant_Accounting_Policie4

Significant Accounting Policies (Details Textual) (USD $)	6 Months Ended			1 Months Ended	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Feb. 24, 2014	Jun. 30, 2014
			NeuroEyeCoach retail [Member]	Series A Warrants [Member]	Series A Warrants [Member]
				Placement Agent Agreement [Member]	Placement Agent Agreement [Member]
Significant Accounting Policies (Textual)	'	'	'	'	'
Software development costs	$25,199	'	'	'	'
Capitalized software development cost	55,039	0	'	'	'
Capitalized software development cost additions	21,463	'	'	'	'
Total capitalized value	$119,106	'	$8,377	'	'
Shares issued during period	'	'	'	402,033	34,723

Notes_Payable_Details

Notes Payable (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Components of notes payable	'	'
Total Related Party Notes Payable:	$2,247,037	'
Convertible debentures issued on December 29, 2009 and February 3, 2010 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	441,362	441,362
Convertible debentures issued on March 31, 2010 and October 14, 2010 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	175,000	175,000
Debentures payable issued on October 26, 2010 and November 15, 2010 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	400,000	400,000
Convertible debenture issued on November 15, 2010 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	300,000	300,000
Short term, unsecured notes payable issued on July to December 2012 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	300,900	300,900
Short term, unsecured notes payable issued on August to December 2012 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	115,550	115,550
Short term, unsecured notes payable issued on January to September 2013 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	324,225	324,225
Short term, unsecured notes payable issued on August 9 to December 2013 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	'	91,519
Short term, unsecured notes payable issued on Januar to September 2013 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	190,000	190,000
Short term, unsecured notes payable issued on August 9 to December 2013 [Member] 1	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	'	20,000
Short term, unsecured notes payable issued on August 9 to December 2013 [Member] 1	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	'	15,000
Term notes issued on March 25, 2011[Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	300,000	300,000
Short term, unsecured notes payable issued to Craig Kirsch on August to December 2012 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	98,550	98,550
Short term, unsecured notes payable issued September 2012 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	'	42,900
Short term, unsecured notes payable issued to Craig Kirsch on June to September 2013 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	10,000	10,000
Unsecured loans issued in August 9 to December 2013 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	'	3,000
Term notes issued on October 22, 2013 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	'	100,000
Insurance policy finance agreements [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	11,445	23,736
Other Notes Payable [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	$419,995	$578,186

Notes_Payable_Details_1

Notes Payable (Details 1) (USD $)	Jun. 30, 2014
Related Party	'
Extinguishment of Debt [Line Items]	'
2014	'
2015	'
2016	'
2017	2,247,037
Total	2,247,037
Other	'
Extinguishment of Debt [Line Items]	'
2014	311,445
2015	'
2016	'
2017	108,550
Total	$419,995

Notes_Payable_Details_Textual

Notes Payable (Details Textual) (USD $)

0 Months Ended

6 Months Ended

0 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

0 Months Ended

6 Months Ended

Feb. 03, 2010

Dec. 29, 2009

Oct. 14, 2010

Mar. 31, 2010

Nov. 15, 2010

Oct. 26, 2010

Nov. 15, 2010

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Mar. 25, 2011

Jun. 30, 2014

Sep. 30, 2012

Jun. 30, 2014

Jun. 30, 2014

Oct. 22, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Convertible debentures issued on December 29, 2009 and February 3, 2010 [Member]

Convertible debentures issued on December 29, 2009 and February 3, 2010 [Member]

Convertible debentures issued on March 31, 2010 and October 14, 2010 [Member]

Convertible debentures issued on March 31, 2010 and October 14, 2010 [Member]

Debentures payable issued on October 26, 2010 and November 15, 2010 [Member]

Debentures payable issued on October 26, 2010 and November 15, 2010 [Member]

Convertible debenture issued on November 15, 2010 [Member]

Short term, unsecured notes payable issued on July to December 2012 [Member]

Short term, unsecured notes payable issued on August 9 to December 2013 [Member]

Short term, unsecured notes payable issued on August 9 to December 2013 [Member] 1

Term notes issued on March 25, 2011[Member]

Short term issued in August to December 2012 [Member]

Short term, unsecured notes payable issued September 2012 [Member]

Insurance policy finance agreements [Member]

Unsecured loans issued in August 9 to December 2013 [Member]

Term notes issued on October 22, 2013 [Member]

Short term, unsecured notes payable issued on August 9 to December 2013 [Member] 1

Short term, unsecured notes payable issued on August 9 to December 2013 [Member] 2

Short term, unsecured notes payable issued to Craig Kirsch on August to December 2012 [Member]

Short term, unsecured notes payable issued on August to December 2012 [Member]

Short term, unsecured notes payable issued to Craig Kirsch on June to September 2013 [Member]

Notes Payable (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of convertible debentures

$70,000

$371,362

$90,000

$85,000

$322,500

$77,500

$350,000

$300,900

$91,519

$20,000

'

$325,744

$42,900

$28,525

$210,000

$100,000

$115,550

$15,000

$98,550

$3,000

$10,000

Term notes payables

'

'

'

'

'

'

'

'

'

'

300,000

'

'

'

'

'

'

'

'

'

'

Percentage of company's common stock hold by beneficial owner

50.00%

50.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest rate on debentures

6.00%

6.00%

6.00%

6.00%

6.00%

6.00%

6.00%

6.00%

6.00%

6.00%

'

6.00%

6.00%

'

6.00%

16.00%

6.00%

6.00%

6.00%

6.00%

6.00%

Conversion price

$1.88

$1.88

$2.63

$2.63

'

'

$2.85

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Repayment of convertible debt

'

'

'

'

'

'

50,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest rate on term notes

'

'

'

'

'

'

'

'

'

'

16.00%

'

'

'

'

'

'

'

'

'

'

Number of common stock purchased by issuance of warrants

'

'

'

'

'

'

'

'

'

'

400,000

'

'

'

'

'

'

'

'

'

'

Exercise price of warrants

'

'

'

'

'

'

'

'

'

'

$1.80

'

'

'

'

'

'

'

'

'

'

Period of warrants

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'

'

'

'

'

Debt instrument, maturity date, description

'

'

'

'

'

'

'

'

'Due on demand or one year after the issue date

'Due on demand or one year after the issue date

'

'

'

'

'Due on demand or one year after the issue date

'

'Due on demand or one year after the issue date

'Due on demand or one year after the issue date

'Due on demand or one year after the issue date

'Due on demand or one year after the issue date

'Due on demand or one year after the issue date

Debt instruments, original maturity date

31-Aug-10

31-Aug-10

31-Aug-11

31-Aug-11

31-Aug-11

31-Aug-11

31-Dec-12

'

'

'

25-Jun-11

'

'

'

'

30-Nov-13

'

'

'

'

'

Debt instruments, extended maturity date description

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Due date has been extended to January 2, 2017

Due date has been extended to January 2, 2017

Due date has been extended to January 2, 2017

Due date has been extended to January 2, 2017

Due date has been extended to January 2, 2017

Due date has been extended to January 2, 2017

Due date has been extended to January 2, 2017

Due date has been extended to January 2, 2017,

Due date has been extended to January 2, 2017

Due date has been extended to January 2, 2017

The due date for this note has been extended to January 2, 2015,

due date has been extended to January 2, 2017

Due date has been extended to January 2, 2017

The due date for this note has been extended to January 2, 2017,

The due date for this note has been extended to January 2, 2017

Debt notes repaid description

'

'

'

'

'

'

'

'

'

'This note was repaid in February 2014.

'

'

'This note was repaid in June 2014

'

'These notes were repaid in January and February 2014.

'This note was repaid in January 2014.

'This note was repaid in February 2014.

'This note was repaid in 2014.

'

'This note was repaid in February 2014.

'

Repayments of insurance policy

'

'

'

'

'

'

'

'

'

'

'

'

'

$23,923

'

'

'

'

'

'

'

Segment_Reporting_Geographical2

Segment Reporting, Geographical Information (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Revenue:	'	'	'	'	'
Total Revenue	$298,540	$234,954	$656,662	$466,628	'
Gross Profit:	'	'	'	'	'
Total Gross Profit	262,773	207,060	577,938	408,716	'
Total Assets:	'	'	'	'	'
Total Assets	4,792,678	'	4,792,678	'	2,115,250
Vycor Medical [Member]	'	'	'	'	'
Revenue:	'	'	'	'	'
Total Revenue	203,191	146,358	466,902	277,024	'
Gross Profit:	'	'	'	'	'
Total Gross Profit	177,717	135,152	411,125	251,431	'
Total Assets:	'	'	'	'	'
Total Assets	3,521,581	'	3,521,581	'	799,120
NovaVision [Member]	'	'	'	'	'
Revenue:	'	'	'	'	'
Total Revenue	95,349	88,596	189,760	189,604	'
Gross Profit:	'	'	'	'	'
Total Gross Profit	85,056	71,908	166,813	157,285	'
Total Assets:	'	'	'	'	'
Total Assets	$1,271,097	'	$1,271,097	'	$1,316,130

Segment_Reporting_Geographical3

Segment Reporting, Geographical Information (Details 1) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Revenue:	'	'	'	'	'
Total Revenue	$298,540	$234,954	$656,662	$466,628	'
Gross Profit:	'	'	'	'	'
Total Gross Profit	262,773	207,060	577,938	408,716	'
Total Assets:	'	'	'	'	'
Total Assets	4,792,678	'	4,792,678	'	2,115,250
United States [Member]	'	'	'	'	'
Revenue:	'	'	'	'	'
Total Revenue	238,474	180,792	531,635	360,307	'
Gross Profit:	'	'	'	'	'
Total Gross Profit	207,577	161,140	465,816	317,328	'
Total Assets:	'	'	'	'	'
Total Assets	4,322,406	'	4,322,406	'	1,604,142
Europe [Member]	'	'	'	'	'
Revenue:	'	'	'	'	'
Total Revenue	60,066	54,162	125,027	106,321	'
Gross Profit:	'	'	'	'	'
Total Gross Profit	55,196	45,920	112,122	91,388	'
Total Assets:	'	'	'	'	'
Total Assets	$470,272	'	$470,272	'	$511,108

Segment_Reporting_Geographical4

Segment Reporting, Geographical Information (Details Textual)	6 Months Ended
	Jun. 30, 2014
	Segment
Segment Reporting, Geographical Information (Textual)	'
Number of business segments	2
Number of geographic segments	2

Equity_Details

Equity (Details) (USD $)

0 Months Ended

6 Months Ended

6 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

Aug. 14, 2007

Jun. 30, 2014

Feb. 24, 2014

Jan. 02, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Feb. 24, 2014

Jun. 30, 2014

Jan. 02, 2014

Feb. 24, 2014

Jun. 30, 2014

Jun. 30, 2014

Feb. 24, 2014

Jun. 30, 2014

Jan. 02, 2014

Feb. 24, 2014

Steven Girgenti [Member]

Dr Oscar Bronsther [Member]

Alvaro Pascual - Leone [Member]

Jason Barton [Member]

Jose Romano [Member]

Josef Zihl [Member]

Fountainhead Capital Partners Limited [Member]

Lowell Rush [Member]

Securities Offering [Member]

Consulting and Advisory Services [Member]

Consulting and Advisory Services [Member]

Consulting and Advisory Services [Member]

Consulting and Advisory Services [Member]

Consulting and Advisory Services [Member]

Consulting and Advisory Services [Member]

Common Stock [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series C Preferred Stock [Member]

Del Mar Consulting [Member]

Alex Partners, LLC [Member]

Garden State Securities, Inc (GSS)

J and M Group, Llc [Member]

Fountainhead [Member]

Fountainhead Capital Partners Limited [Member]

Fountainhead Capital Partners Limited [Member]

Placement Agent Agreement [Member]

Placement Agent Agreement [Member]

Fountainhead Capital Partners Limited [Member]

Fountainhead Capital Partners Limited [Member]

Equity (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate sale of closing comprised shares, value

'

'

'

'

'

'

'

'

'

'

'

'

'

$5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants issued to purchase common stock shares, Shares

'

2,777,808

420,838

792,523

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

34,723

210,419

1,388,919

396,262

'

'

'

210,419

1,388,919

396,262

'

Shares issued during period

'

'

'

'

'

'

'

'

'

'

'

792,523

'

'

'

'

'

'

'

'

'

'

'

'

'

402,033

34,723

1,130,621

'

'

'

'

Common Stock, par value (in dollars per share)

'

$0.00

'

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants exercisable period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'3 years

'

'

'

'

Number of shares of common stock percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50.00%

'

'

'

'

'

50.00%

'

'

'

'

Warrant exercise price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.80

$2.05

'

'

'

'

'

$3.08

'

'

'

'

Shares of series C convertible preferred stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15.15

Aggregate investment amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

757,700

Conversion of stock, shares converted

107

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued value

'

'

'

'

'

10,000

10,000

6,250

1,563

3,125

1,437

30,000

3,734

'

'

5,400

3,600

66,000

4,700

43,020

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued shares

'

'

'

'

'

4,516

4,238

2,873

694

1,324

3,125

12,605

8,750

'

'

3,000

2,000

30,000

2,500

18,000

'

'

'

'

'

'

'

'

'

'

'

'

Shares under the original Agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued consulting fee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,426,542

'

'

'

'

'

'

'

Issuance Of Series A Warrants And Placement Agent Warrants Shares

'

2,397,631

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

ShareBased_Compensation_Detail

Share-Based Compensation (Details) (USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Stock Warrants [Member]	'	'
Details of the outstanding rights, options and warrants and value of such rights, options and warrants	'	'
Options Outstanding, Beginning Balance	1,404,599	1,749,874
Number of shares, Granted	4,404,401	'
Number of shares, Exercised	'	-341,941
Number of shares, Cancelled or expired	-582,477	-3,334
Options Outstanding, Ending Balance	5,226,523	1,404,599
Weighted average exercise price per share, Outstanding, Beginning Balance	$3.39	$3.03
Weighted average exercise price per share, Granted	$2.52	'
Weighted average exercise price per share, Exercised	'	$1.49
Weighted average exercise price per share, Cancelled or expired	$4.45	$10.50
Weighted average exercise price per share, Outstanding, Ending balance	$2.54	$3.39
Stock options [Member]	'	'
Details of the outstanding rights, options and warrants and value of such rights, options and warrants	'	'
Options Outstanding, Beginning Balance	5,557	5,557
Number of shares, Granted	'	'
Number of shares, Exercised	'	'
Number of shares, Cancelled or expired	'	'
Options Outstanding, Ending Balance	5,557	5,557
Weighted average exercise price per share, Outstanding, Beginning Balance	$20.25	$20.25
Weighted average exercise price per share, Granted	'	'
Weighted average exercise price per share, Exercised	'	'
Weighted average exercise price per share, Cancelled or expired	'	'
Weighted average exercise price per share, Outstanding, Ending balance	$20.25	$20.25

ShareBased_Compensation_Detail1

Share-Based Compensation (Details 1) (Stock options [Member], USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Stock options [Member]	'	'
Options and warrants expensed	'	'
Risk-free interest rates	0.78%	'
Expected life	'3 years	'
Expected dividends	0.00%	'
Expected volatility	75.00%	'
Vycor Common Stock fair value	$2.05	'

ShareBased_Compensation_Detail2

Share-Based Compensation (Details Textual) (USD $)

1 Months Ended

3 Months Ended

6 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

2 Months Ended

0 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

0 Months Ended

6 Months Ended

Jul. 31, 2013

Jul. 31, 2013

14-May-14

Jun. 30, 2014

Feb. 24, 2014

Jan. 02, 2014

Sep. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Nov. 30, 2013

Nov. 30, 2013

Jan. 02, 2014

Jun. 30, 2014

Jun. 30, 2014

Feb. 29, 2008

Feb. 29, 2008

31-May-10

Feb. 29, 2008

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jan. 02, 2014

Jun. 02, 2013

Jun. 30, 2014

Common Stock [Member]

Stock options [Member]

Stock options [Member]

Stock Warrants [Member]

Stock Warrants [Member]

Del Mar Consulting [Member]

Alex Partners, LLC [Member]

Dr Donald O Rourke [Member]

Board of Directors Chairman [Member]

Scientific Advisory Board [Member]

Stock Option Plan [Member]

Stock Option Plan [Member]

Stock Option Plan [Member]

Stock Option Plan [Member]

Non Employee Stock Compensation [Member]

Non Employee Stock Compensation [Member]

Non Employee Stock Compensation [Member]

Non Employee Stock Compensation [Member]

Non Employee Stock Compensation [Member]

Non Employee Stock Compensation [Member]

Non Employee Stock Compensation [Member]

Non Employee Stock Compensation [Member]

Consulting Agreement [Member]

Extension Agreement [Member]

Extension Agreement [Member]

Advisory Agreement [Member]

Advisory Agreement [Member]

Advisory Agreement [Member]

Stock Warrants [Member]

Chief Executive Officer [Member]

President [Member]

President [Member]

Common Stock [Member]

Steven Girgenti [Member]

Dr Oscar Bronsther [Member]

Alvaro Pascual - Leone [Member]

Jason Barton [Member]

Jose Romano [Member]

Josef Zihl [Member]

Lowell Rush [Member]

Del Mar Consulting [Member]

Alex Partners, LLC [Member]

J and M Group, LLC [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Subsequent Event [Member]

Share-Based Compensation (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ownership percentage of outstanding voting stock for the options to be granted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'More than 10%.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price of options granted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'Not less than 110% of the fair market value of the common stock on the grant date.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Option expired period determined by the board of directors

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'Not extend mare than 10 years from the grant date.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding voting stock expire from grant date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vesting period for employees

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares, Granted

'

'

'

'

'

'

'

'

'

'

4,404,401

'

'

'

'

'

'

'

500,000

'

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of number of shares covered by plan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price per share

'

'

'

'

'

'

'

'

'

'

$2.52

'

'

'

'

'

'

'

$0.14

'

$0.14

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of options vested on first anniversary

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

33.33%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of options vested on second anniversary

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

33.33%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of options vested on third anniversary

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

33.33%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Grant expire date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12-Feb-18

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options cancelled or expired

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

166,667

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation expenses

'

'

'

$316,000

'

'

'

$21,510

'

'

'

'

'

'

'

$36,250

$28,125

'

'

'

'

'

'

'

'

'

'

'

'

$78,620

'

'

'

$66,000

'

Weighted-average remaining contractual life of outstanding options

'

'

'

'

'

'

'

'

'3 years 10 months 17 days

'

'2 years 4 months 6 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation shares issued to nonemployees for services, share

'

'

'

'

'

'

'

18,000

'

'

'

'

33,000

27,000

'

'

'

'

'

'

'

'

4,516

4,238

1,437

1,324

1,324

2,873

3,734

'

3,000

2,000

6,276

'

2,500

Share-based compensation shares issued to nonemployees for services, value

'

'

'

259,727

'

'

'

43,020

'

'

21,510

'

66,000

54,000

'

'

'

'

'

'

'

15,625

10,000

10,000

3,125

3,125

3,125

6,250

8,750

'

5,400

3,600

15,000

'

4,700

consultancy agreement period

'

'

'

'

'

'

'

'

'

'

'

'

'3 months

'3 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total unrecognized compensation costs related to warrant and stock awards and non-vested options

'

'

'

'

'

'

175,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued during period, Restricted Stock, shares

30,000

28,750

45,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

30,000

'

Stock Issued during period, Restricted Stock, value

66,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

66,000

'

Warrants issued to purchase common stock shares, Shares

'

'

'

2,777,808

420,838

792,523

'

'

'

'

'

'

'

'

7,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants issued to purchase common stock shares, Value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$5,522

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants issue to purchase commmon stock of share at an exercise price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$3.08

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Warrant Liability	$37,152	'
Level 1 [Member]	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Warrant Liability	'	'
Level 2 [Member]	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Warrant Liability	'	'
Level 3 [Member]	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Warrant Liability	$37,152	'

Fair_Value_Measurements_Detail1

Fair Value Measurements (Details 1) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014
			Fair Value, Inputs, Level 3 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'	'
Balance at December 31, 2013	$37,152	'	'
Issuance of Series A Warrants and Placement Agent Warrants as part of Offering Units on January 2, January 31, February 24, February 28 and March 31, April 25, 2014	'	'	2,103,195
Change in fair value during period	'	'	269,993
Reduction In Liability From Waiver Anti Dilution	'	'	-2,336,036
Balance at March 31, 2014	$37,152	'	$37,152

Fair_Value_Measurements_Detail2

Fair Value Measurements (Details 2) (Warrant [Member], USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Warrant [Member]	'	'
Fair Value Assumptions [Abstract]	'	'
Risk-free interest rates	'	'
Risk-free interest rates, Minimum	0.68%	'
Risk-free interest rates, Maximum	0.93%	'
Expected life	'3 years	'0 years
Expected dividends	0.00%	'
Expected volatility	'	'
Expected volatility, Minimum	71.00%	'
Expected volatility, Maximum	97.00%	'
Vycor Common Stock fair value minimum	$1.88	'
Vycor Common Stock fair value maximum	$2.70	'

Fair_Value_Measurements_Detail3

Fair Value Measurements (Details Textual)	6 Months Ended
	Jun. 30, 2014
Fair Value measurements (Textuals)	'
Issuance Of Series A Warrants And Placement Agent Warrants Shares	2,397,631
Fair Value, Measurements, Recurring [Member]	'
Fair Value measurements (Textuals)	'
Issuance Of Series A Warrants And Placement Agent Warrants Shares	34,723

Commitments_and_Contingencies_

Commitments and Contingencies (Details)	1 Months Ended		6 Months Ended
	Jun. 30, 2012	Jun. 30, 2012	Jun. 30, 2014	Jun. 30, 2013
	USD ($)	EUR (€)	USD ($)	USD ($)
			sqft
Commitments and Contingencies (Textual)	'	'	'	'
Area of leased building (sq. ft)	'	'	10,000	'
Rent expenses plus sales tax (per month)	'	'	$14,260	'
Term of lease	'	'	'5 years 6 months	'
Lease expiration date	'	'	31-Jul-17	'
Approximate preliminary assessed trade tax	94,000	75,000	'	'
Rent expense	'	'	$99,160	$96,444

Consulting_and_Other_Agreement1

Consulting and Other Agreements (Details) (USD $)	1 Months Ended		3 Months Ended	0 Months Ended	1 Months Ended						6 Months Ended
	Jul. 31, 2013	Jul. 31, 2013	14-May-14	Jan. 02, 2014	Nov. 30, 2013	Nov. 30, 2012	Nov. 30, 2013	Nov. 30, 2012	Sep. 30, 2014	Mar. 31, 2014	Jun. 30, 2014
				Fountainhead [Member]	Del Mar Consulting [Member]	Del Mar Consulting [Member]	Alex Partners, LLC [Member]	Alex Partners, LLC [Member]	Hayden IR, LLC	Hayden IR, LLC	Hayden IR, LLC
Consulting and Other Agreements (Textual)	'	'	'	'	'	'	'	'	'	'	'
Consulting agreement duration	'	'	'	'	'	'12 months	'	'12 months	'	'12 months	'
Shares received under consulting agreement, value	'	'	'	'	$33,000	'	$27,000	'	'	$8,500	'
Cash payment pursuant to consulting agreement	'	'	'	'	66,000	'	54,000	'	'	'	'
Maximum cash payment for consulting services (monthly)	'	'	'	10,000	'	'	'	'	'	'	'
Minimum cash payment for consulting services	'	'	'	$5,000	'	'	'	'	'	'	'
Stock issued during period, Restricted Stock, shares	30,000	28,750	45,000	'	'	'	'	'	18,000	36,000	18,000
Description of agreement	'(i) 90 days from the date of execution of the Agreement or (ii) the end of the offering period of any securities financing undertaken by the Company in connection with the Placement Agent Agreement.	'	'	'	'	'	'	'	'	'	'

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)

Jun. 30, 2014

Dec. 31, 2013

Jan. 02, 2014

Jun. 30, 2014

Jan. 02, 2014

Jan. 02, 2014

Aug. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Oct. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Consulting Agreement [Member]

Consulting Agreement [Member]

Employment Agreements [Member]

Conversion Agreement [Member]

Subsequent Event [Member]

Fountainhead [Member]

Fountainhead [Member]

Fountainhead [Member]

Peter Zachariou [Member]

Peter Zachariou [Member]

David Cantor [Member]

David Cantor [Member]

Fountainhead and Peter Zachariou [Member]

Consulting Agreement [Member]

Secured Loan One [Member]

Consulting Agreement [Member]

Consulting Agreement [Member]

Subsequent Event [Member]

Related Party Transactions (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loan amount

'

$2,373,556

'

'

'

'

$10,000

'

'

$35,000

'

'

'

'

$2,247,037

Extension of maturity date

'

'

'Fountainhead amended their Consulting Agreement to extend the term of the Consulting Agreement to to January 2, 2015.

'

'

'

'

'

'

'

'

'

'

'

'

Loan repayment term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'Fountainhead and Peter Zachariou agreed to extend the maturity of all of the Company's debt obligations due to them due to as of August 9, 2013 (aggregating $2,247,037) to January 2, 2017, subject to the earlier repayment of such debt upon the occurrence of certain specified conditions.

Repayment of debt

'

'

'

'

'

'

'

91,519

202,683

'

20,000

247

15,000

69,198

'

Annual compensation of employment agreements

'

'

'

'

110,000

'

'

'

'

'

'

'

'

'

'

Description of employment agreements

'

'

'

'

'The aforementioned Employment Agreements provide for annual compensation of $110,000, payment of which is deferred for 12 months from the Effective Date and is subject to the achievement of certain enumerated milestone conditions.

'

'

'

'

'

'

'

'

'

'

Decrease in retainer payable to Fountainhead

'

'

10,000

'

'

'

'

'

'

'

'

'

'

'

'

Retainer payable to Fountainhead

'

'

5,000

'

'

'

'

'

'

'

'

'

'

'

'

Accrued consulting fee

'

'

'

'

'

1,426,542

'

'

'

'

'

'

'

'

'

Common Stock issued to Fountainhead

$1,083

$675

'

$30,000

'

'

'

'

'

'

'

'

'

'

'

Common Stock issued to Fountainhead, Shares

10,835,945

6,757,225

'

12,605

'

'

'

'

'

'

'

'

'

'

'

Subsequent_Events_Details_Text

Subsequent Events (Details Textual) (Subsequent Event [Member], USD $)	2 Months Ended			0 Months Ended
	Aug. 31, 2014	Aug. 31, 2014	Aug. 31, 2014	Aug. 05, 2014
	Steven Girgenti [Member]	Alvaro Pasual Leone [Member]	Josef Zihl [Member]	Fountainhead Capital Partners Limited [Member]
	Common Stock [Member]	Common Stock [Member]	Common Stock [Member]
Subsequent Events (Textual)	'	'	'	'
Common stock issued in consideration for services	$5,000	$1,563	$3,125	'
Common stock issued in consideration for services, Shares	2,016	570	1,141	'
Debt Extinguishment and conversion to Preferred	'	'	'	'This equity exchange will result in Vycor's Shareholders' Equity being increased by $2,355,587, equivalent to the current debt. Under the terms of the exchange, the Fountainhead Parties will receive $2,355,587 of Vycor Series D preferred shares ("Series D") that will be convertible into Vycor Shares at a price of $2.15. The Series D will carry a dividend of 7% per annum, payable in cash or Series D at the Company's option, rising to 12% payable in cash after two years. The Company is able to redeem the Series D at par at any time, at its sole option. The Fountainhead Parties will also receive 3-year warrants equivalent to 75% of the Vycor Shares received in the exchange on a converted basis, exercisable at $3.08. After three years, if the Series E has not then been redeemed or converted, the Fountainhead Parties will receive additional warrants equivalent to 50% of the shares then held, exercisable at the then market price.
Debt instrument convertible value	'	'	'	$2,355,587
Shares issued price per share	'	'	'	$4.50
Warrants expiration description	'	'	'	'The Company agreed to extend the life of certain of Fountainhead's existing warrants expiring in 2015 to the same 3-year term as the warrants being issued under the exchange.